Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmic, vitamins, minerals, dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, and analgesics; and anti-oxidants, balanced energy and protein drinks, and vitamins and nutraceuticals, as well as various active pharmaceutical ingredients. It provides its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Vitcofol, Ziglim, Ziglim Plus 2, Electral, and Enerzal brand names. The company was founded in 1936 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for FDC
Revenue projections for FDC



Financial Ratios:

currentRatio 0.00000
forwardPE 0.00000
debtToEquity 0.85200
earningsGrowth -0.23700
revenueGrowth 0.00100
grossMargins 0.66139
operatingMargins 0.08069
trailingEps 13.32000
forwardEps 23.30000

FDC's low growth in earnings and revenue indicates a potential decline in profits. This suggests that the company could be facing financial challenges, making it harder to sustain its current profit margins.
FDC Limited's negative gross and operating margins point to financial difficulties, as the company is incurring losses at both the production and operational levels. This suggests a potential decline in profitability and raises concerns about its financial outlook.
FDC's forward EPS exceeding its trailing EPS means that the company is expected to increase profitability in the current financial year. This reflects improved earnings potential, signaling that FDC is likely to outperform its previous year's financial performance.

Recommendation changes over time:

Recommendations trend for FDC
Recommendations trend for FDC


With analysts showing a buy bias for FDC, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning FDC as a safe and profitable place for investors to allocate their funds and seek growth.